Merz Aesthetics Reveals Global Data on the Connection Between Confidence, Self-Affirmation and Aesthetic Treatments
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, today announced the findings of its inaugural global study, Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation. The study explored the role confidence plays in daily life and overall well-being, as well as the connection between our internal selves and outward expression.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250129954824/en/
Graphic: Merz Aesthetics
As part of its Confidence to Be platform, Merz Aesthetics surveyed 15,000 adults from around the world who have had an aesthetic treatment in the past or are open to having one in the near future. The Pillars of Confidence study revealed that a global majority of study participants have a strong sense of self-confidence, with 72% agreeing with the statement, “I am confident in who I am.”
The findings of the Pillars of Confidence study also link external appearance to internal self-concept. When it comes to aesthetic treatments specifically, 73% of respondents reported saying they feel “empowered” after having an aesthetic treatment, 69% seek aesthetic treatments to reflect how they feel inside and 72% said that aesthetic treatments impact how they view themselves.
Conducted in partnership with Ipsos*, one of the largest market research and polling companies globally, the Pillars of Confidence study engaged 15,000 adults aged 21 to 75** from 15 countries. Participating regions and countries included:
- Asia-Pacific: China, South Korea, Thailand
- Europe, the Middle East & Africa: France, Germany, Italy, Spain, the United Kingdom and the United Arab Emirates
- Latin America: Brazil, Colombia, Costa Rica, Mexico
- North America: United States, Canada
“Since becoming a standalone global business nearly five years ago, Merz Aesthetics has been committed to our purpose of fueling confidence by helping people look better, feel better and live better. We believe in the importance of feeling confident and what makes you feel like the best version of yourself—however you define it,” said Bob Rhatigan, CEO, Merz Aesthetics. “Our Pillars of Confidence research shows what we anecdotally knew to be true—that aesthetic treatments appear to do more than just enhance our appearance; they can help people feel empowered and support their self-confidence journey.”
“The Pillars of Confidence data shows how aesthetic treatments enable patients to take an active role in aligning their self-perception with their outward appearance,” said Dr. Shannon Humphrey, cosmetic dermatologist, medical director at Humphrey & Beleznay Cosmetic Dermatology and clinical associate professor at the University of British Columbia. “As a physician, I see this impact every day. These insights can help us better understand and support our patients as they work toward personal empowerment, which ultimately enhances the care we provide.”
Whether it’s the things we say, the people we surround ourselves with, or our choices around aesthetic treatments, Merz Aesthetics believes that every person's journey to look, feel and live their best is unique. With a purpose to fuel confidence worldwide, Merz Aesthetics hopes that the data-backed insights of the Pillars of Confidence study will inspire meaningful conversations that enable even more people to celebrate being their authentic selves, both inside and out.
For more information on the Pillars of Confidence study and to download a full report of the findings, please visit www.merzaesthetics.com/confidence.
*Merz Aesthetics. (2025). Pillars of Confidence: Global Insights on Aesthetics and Self-Affirmation. Supported by research partner Ipsos.
**Age range in Asia-Pacific region was 21 to 65.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
© 2025 Merz North America, Inc. All rights reserved. Merz, Merz Aesthetics and the Merz Aesthetics Confidence To Be Logo are trademarks and/or registered trademarks of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129954824/en/
Contacts
Media Contact
Merz Aesthetics
Global Corporate Communications
6501 Six Forks Road, Raleigh NC 27615
919-302-3296
media@merz.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 202531.1.2025 15:30:00 EET | Press release
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer. The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285. About Coincheck Group N.V. Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coi
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer31.1.2025 15:00:00 EET | Press release
Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE:45680) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast01 phase 3 trial published in the Journal of Clinical Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast01, datopot
REPLY: Coding and Cybersecurity, Registration Is Now Open for the Reply Hack The Code Challenge 202531.1.2025 13:42:00 EET | Press release
Reply has announced the opening of registrations for the ReplyHackThe Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131992792/en/ Reply has announced the opening of registrations for the Reply Hack The Code Challenge 2025, the leading online team coding competition, which will take place on March 12th 2025. This year's challenge will combine programming and cybersecurity for the first time, offering participants the opportunity to tackle algorithmic problems and cybersecurity challenges. (Photo: Business Wire) The competition follows the format of previous events, with two parallel challenges: the Standard Edition, aimed at university
GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand31.1.2025 10:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250130241464/en/ GE HealthCare’s contrast media manufacturing site in Cork (Photo: Business Wire) Contrast media are injectable diagnostic imaging agents used to enhance visualization of organs, blood vessels and tissues during medical imaging. Global demand for iodine-based contrast media, used in X-Ray, Computed Tomography (CT) and Interventional procedures is expected to double in the next decade, driven by ageing populations and the increasing global prevalence of chronic disorders. In 2024, the Carrigtohill facility, a
Vertex Announces CASGEVY ® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England31.1.2025 09:00:00 EET | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD patients in England now have access to the therapy following the prior agreement for transfusion-dependent beta thalassemia (TDT) patients announced last August. “Today is an important day for the sickle cell community who have gone too long without treatments that address the underlying cause of their devastating disease,” said Ludovic Fenaux, Senior Vice President, Vertex International. “We are pleased to have reached this new agreement that ensures both eligible SCD and TDT patients can now be treated with CASGEVY, recognizing the value a one-time treatment can provide to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom